New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
10:46 EDTMAC, PTR, TTM, STT, ALKSHigh option volume stocks: ALKS TTM MAC STT PTR
News For ALKS;TTM;MAC;STT;PTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:04 EDTALKSAlkermes announces initiation of second Phase 3 study of ALKS 3831
Subscribe for More Information
February 9, 2016
09:07 EDTALKSAlkermes CEO remains optimistic on depression drug, Forbes reports
Subscribe for More Information
February 5, 2016
07:51 EDTALKSWoodford calls Alkermes, Prothena selloffs 'greatly overdone'
British businessman Neil Woodford's Woodford Investment Management said it added to Alkermes (ALKS) and Prothena (PRTA) positions at what it considers to be "extremely attractive valuation levels." In its January letter to investors, the fund says the recent share price moves "look greatly overdone." Woodford also sold its position in GlaxoSmithKline (GSK) and initiated a new stake in Theravance Biopharma (TBPH). The company "retains a valuable economic interest in the future commercial potential of the respiratory franchise being developed in partnership with GlaxoSmithKline," the fund wrote. It also has "some very interesting, albeit earlier-stage, assets in therapeutic areas such as chronic obstructive pulmonary disease, cardiovascular & renal disease," it added. Woodford made no mention of Northwest Biotherapeutics (NWBO) in the letter, a company he invested in last year. Woodford Investment Management, established in 2014, describes itself as the "the opportunity for Neil Woodford, one of the UK's most highly-regarded fund managers, to distil his 30 years of experience and learning into a business founded on his own principles." Reference Link
06:00 EDTSTTState Street close to deal to buy GE asset management unit, Reuters reports
Subscribe for More Information
February 3, 2016
16:24 EDTMACMacerich sees 2016 FFO $4.05-$4.15, consensus $4.04
Subscribe for More Information
16:24 EDTMACMacerich reports Q4 FFO $1.12, consensus $1.07
Reports Q4 revenue $320.8M, consensus $329.6M.
February 2, 2016
08:59 EDTALKSLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
January 29, 2016
07:59 EDTALKSAlkermes management to meet with JPMorgan
Subscribe for More Information
January 28, 2016
10:13 EDTALKSOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use